Advertisement

Related Videos

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Peter Clark, MA, MD, FRCP: A Payer Perspective

Opportunities to Optimize Cancer Policies Panel Discussion

Advertisement

Advertisement




Sep
03
Today In Oncology
ADC/Immunotherapy Combination Shows Activity in Treatment-Resistant Nasopharyngeal Carcinoma
ACS Publishes Report on Cancers in Asian American, Native Hawaiian, and Pacific Islander People
The 2026 ASCO Annual Meeting Geriatric Oncology Update: The Next Challenge Is Implementation
MD Anderson President Announces Retirement, Shares Leadership Transition Plans
ASCENT-04 Exploratory Analysis: Sacituzumab Govitecan Plus Pembrolizumab Improves PFS2, Delays Next Treatment
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo